A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers

Summary

This randomized, observer-blinded, placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5469754 in healthy volunteers. Subjects will be randomized in cohorts to receive single ascending intravenous or subcutaneous doses of RO5469754 or placebo. In-clinic period will be from Day -1 to Day 4, with a safety follow-up of 15 weeks after dosing.

Timeline

Start

2011-11-07

Primary completion

2012-09-03

Completion

2012-09-03

Drugs

Indications

No indication recorded.